Detection of HPV subtypes by mass spectrometry in FFPE tissue specimens: A reliable tool for routine diagnostics

Journal of Clinical Pathology

Volumn 70, Issue 5, 2017, Pages 417-423

  Kriegsmann, Mark ^a   Wandernoth, Petra ^b   Lisenko, Katharina ^a   Casadonte, Rita ^c   Longuespée, Rémi ^c   Arens, Norbert ^b   Kriegsmann, Jörg ^b,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Molecular Pathology   (Germany)

^c PROTEOPATH GMBH   (Germany)

^d Institute for Histology Cytology and Molecular Diagnostics   (Germany)

Author keywords

DIAGNOSTICS; GYNAECOLOGICAL PATHOLOGY; HPV; INFECTIONS; MOLECULAR PATHOLOGY

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; FEMALE; FORMALIN FIXED PARAFFIN EMBEDDED; GENOTYPE; HUMAN; HUMAN TISSUE; HYBRIDIZATION; MALE; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TISSUE SECTION; VIRUS DETECTION; VIRUS STRAIN; WART VIRUS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; GENETICS; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

COST-BENEFIT ANALYSIS; FEMALE; GENOTYPE; HUMANS; MALE; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PARAFFIN EMBEDDING; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84994633874     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2016-204017     Document Type: Article

References (23)

1. Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 2015;136:2752-60.
2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
3. WHO. Globocan: Estimated Cancer Incidence, Mortality and Prevalence Worldwide. 2012.
4. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
5. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23.
6. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
7. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
8. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
9. Dok R, Nuyts S. HPV positive head and neck cancers: molecular pathogenesis and evolving treatment strategies. Cancers (Basel) 2016;8.
10. Beltrão M, Wanderley MS, de Santana NA, et al. Site of infections associated with human papillomavirus. Arch Gynecol Obstet 2015;291:481-91.
11. Kriegsmann M, Arens N, Endris V, et al. Detection of KRAS, NRAS and BRAF by mass spectrometry-a sensitive, reliable, fast and cost-effective technique. Diagn Pathol 2015;10:132.
12. National Cancer Institute: Surveillance E, and End Results Program. SEER Stat Fact Sheets: Cervix Uteri Cancer. Secondary SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html
13. Munagala R, Donà MG, Rai SN, et al. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol 2009;34:263-71.
14. Patel DA, Shih YJ, Newton DW, et al. Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirus. J Virol Methods 2009;160:78-84.
15. Gravitt PE, Coutlee F, Iftner T, et al. New technologies in cervical cancer screening. Vaccine 2008;26(Suppl 10):K42-52.
16. Cooper WA, Yu B, Yip PY, et al. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J Clin Pathol 2013;66:744-8.
17. Cricca M, Marasco E, Alessandrini F, et al. High-throughput genotyping of high-risk Human Papillomavirus by MALDI-TOF Mass Spectrometry-based method. New Microbiol 2015;38:211-23.
18. Vaccarella S, Söderlund-Strand A, Franceschi S, et al. Patterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study. PLoS ONE 2013;8: e71617.
19. Soderlund-Strand A, Dillner J. High-throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol Biomarkers Prev 2013;22:242-50.
20. Jing L, Zhong X, Huang W, et al. HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study. BMC Infect Dis 2014;14:388.
21. Yi X, Li J, Yu S, et al. A new PCR-based mass spectrometry system for high-risk HPV, part I: methods. Am J Clin Pathol 2011;136:913-19.
22. Peng J, Gao L, Guo J, et al. Type-specific detection of 30 oncogenic human papillomaviruses by genotyping both E6 and L1 genes. J Clin Microbiol 2013;51:402-8.
23. Basu P, Chandna P, Bamezai RN, et al. MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer. J Clin Microbiol 2011;49:3537-44.